Grace Therapeutics, Inc. Finite-Lived Intangible Assets, Net
Grace Therapeutics, Inc. (GRCE) had Finite-Lived Intangible Assets, Net of $41.13 million as of 2024-03-31, per its 10-K filed 2024-06-21.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2024-06-21
- 2024-03-31: Finite-Lived Intangible Assets, Net $41.13M.
- 2023-03-31: Finite-Lived Intangible Assets, Net $41.13M.
- 2022-03-31: Finite-Lived Intangible Assets, Net $69.81M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2024-03-31 | $41.13M 10-K · filed 2024-06-21 |
| 2023-03-31 | $41.13M 10-K · filed 2024-06-21 |
| 2022-03-31 | $69.81M 10-K · filed 2024-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |